Stallion India Fluorochemicals Limited has issued a revised outcome of its Rights Issue Committee meeting to correct an inadvertent clerical error regarding the face value of equity shares. The company submitted the correction on March 2, 2026, to both the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Face Value Correction

The company clarified that due to an inadvertent clerical error, the face value of equity shares was incorrectly mentioned as Re. 1.00 instead of Rs. 10.00 in the earlier intimation. The revised disclosure supersedes the earlier communication to the extent of this correction.

Rights Issue Allotment Details

The Rights Issue Committee approved the allotment of 3,67,60,483 fully paid-up equity shares having face value of Rs. 10.00 each on a rights basis. The allotment was made in the ratio of 19:41, meaning 19 rights equity shares for every 41 fully paid-up equity shares held by eligible shareholders at a price of Rs. 99.00 per equity share on the record date of February 11, 2026.

Updated Capital Structure

Following the rights issue allotment, the company's paid-up equity share capital has been updated with the correct face value. The allotment was conducted pursuant to the Letter of Offer dated February 12, 2026, and the Basis of Allotment approved by BSE Limited, which served as the Designated Stock Exchange for this issue.

Committee Meeting and Regulatory Compliance

The Rights Issue Committee meeting was held on March 2, 2026, at the company's registered office located at 2, A Wing, Knox Plaza, Off Link Road, Mindspace, Malad – West, Mumbai. The meeting commenced at 6:40 PM and concluded at 7:00 PM. The committee also approved the extinguishment of lapsed rights entitlements and deactivation of ISIN of rights entitlements INE0RYC20010.

Stallion India Fluorochemicals Limited has secured a significant milestone in its expansion strategy with RIICO's approval for land allotment for its proposed Hydrofluoroolefin (HFO) manufacturing plant in Rajasthan. The development strengthens the company's position in the fluorochemicals sector and supports its long-term growth objectives in specialty chemicals manufacturing. The Co-MD has expressed confidence in achieving 30-35% revenue growth over the next three years through strategic initiatives.

Land Allotment Details

The company received approval for Plot No. SP2-9 measuring approximately 53,369 sq. mtrs at the RIICO Industrial Area, Ukhalliya, District Bhilwara, Rajasthan. This new allocation is strategically positioned adjacent to the company's existing land holdings in the same industrial area.

Strategic Manufacturing Layout

The contiguous location of these three adjoining plots enables Stallion India Fluorochemicals to develop a fully integrated manufacturing layout. According to Managing Director & CEO Mr. Shazad Rustomji, this configuration will facilitate shared infrastructure, utilities, security, administration, and common factory management, creating operational synergies and supporting cost optimization as operations scale.

Investment and Timeline

The proposed HFO manufacturing facility represents an investment of approximately ₹200 crore with the start of work planned in 2027. This follows the company's R-32 project, which is targeted for commissioning by October 2026. HFOs represent the next phase of low-global-warming-potential refrigerant technologies and will significantly strengthen the company's product portfolio and long-term competitiveness.

RIPS-2024 Incentives

The Rajasthan project will be eligible for incentives under RIPS-2024, including capex-linked benefits. The incentive structure includes:

• SGST-linked incentives
• Capital and performance-linked support
• Interest subvention
• Employment-linked benefits

These benefits can cumulatively extend up to 100% of the eligible fixed capital investment, subject to approvals and eligibility conditions, significantly enhancing project viability and long-term returns.

Growth Outlook

Backed by these strategic initiatives, the Co-MD has expressed confidence in achieving the targeted 30–35% revenue CAGR over the next three years. The expansion aligns with India's vision of self-reliance in specialty chemicals and fluorochemicals while building a strong domestic manufacturing base for sustainable long-term value creation.